John Strickler, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box_2823, Durham, NC 27710
Phone (919) 668-6608
Email address john.strickler@duke.edu
In Their Words

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2008 - 2011
  • Residency, Medicine, University of Washington, 2005 - 2008
  • M.D., University of Chicago, 2005

Grants

Publications

Bekaii-Saab, T, Kim, R, Kim, TW, O'Connor, JM, Strickler, JH, Malka, D, Sartore-Bianchi, A, Bi, F, Yamaguchi, K, Yoshino, T, and Prager, GW. "Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice." Clinical Colorectal Cancer 18, no. 1 (March 2019): e117-e129. (Review)

PMID
30598357
Full Text

Parseghian, CM, Loree, JM, Morris, VK, Liu, X, Clifton, KK, Napolitano, S, Henry, JT, Pereira, AA, Vilar, E, Johnson, B, Kee, B, Raghav, K, Dasari, A, Wu, J, Garg, N, Raymond, VM, Banks, KC, Talasaz, AA, Lanman, RB, Strickler, JH, Hong, DS, Corcoran, RB, Overman, MJ, and Kopetz, S. "Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge." Annals of Oncology : Official Journal of the European Society for Medical Oncology 30, no. 2 (February 2019): 243-249.

PMID
30462160
Full Text

Turner, MC, Keenan, JE, Rushing, CN, Gulack, BC, Nussbaum, DP, Benrashid, E, Hyslop, T, Strickler, JH, Mantyh, CR, and Migaly, J. "Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response." January 11, 2019.

PMID
30635829
Full Text

Graham, CN, Christodoulopoulou, A, Knox, HN, Sabatelli, L, Hechmati, G, Garawin, T, and Strickler, JH. "A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US." Journal of Medical Economics 21, no. 11 (November 2018): 1075-1083.

PMID
30091652
Full Text

Strickler, JH, Weekes, CD, Nemunaitis, J, Ramanathan, RK, Heist, RS, Morgensztern, D, Angevin, E, Bauer, TM, Yue, H, Motwani, M, Parikh, A, Reilly, EB, Afar, D, Naumovski, L, and Kelly, K. "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 33 (November 2018): 3298-3306.

PMID
30285518
Full Text

Klempner, SJ, Bendell, J, Villaflor, VM, Tenner, L, Stein, S, Sirard, CA, Newman, W, Kagey, M, Schlienger, K, and Strickler, J. "Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies." 43rd ESMO Congress (ESMO). Munich, GERMANY. October 19, 2018 - October 23, 2018.: OXFORD UNIV PRESS, October 1, 2018.

Scholars@Duke

Camidge, R, Heist, RS, Goldman, J, Angevin, E, Strickler, J, Morgensztern, D, Barve, M, Bauer, TM, Vokes, EE, Yi, T, Motwani, M, Parikh, A, Wu, J, and Kelly, K. "An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T plus E) in non-small cell lung cancer (NSCLC)." 43rd ESMO Congress (ESMO). Munich, GERMANY. October 19, 2018 - October 23, 2018.: OXFORD UNIV PRESS, October 1, 2018.

Scholars@Duke

Wainberg, Z, Strickler, J, Gordon, M, Barve, M, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Naumovski, L, and Hamilton, E. "Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.

Scholars@Duke

Wainberg, Z, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Blaney, M, Naumovski, L, and Strickler, J. "ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.

Scholars@Duke

Bekaii-Saab, T, Marcello, K, Fisher, G, Kopetz, S, Strickler, J, Venook, A, and Obholz, K. "Variability of current global practice patterns in the management of metastatic colorectal cancer." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.

Scholars@Duke

Pages